GUEST COLUMNISTS

• Why Are We Still Talking About Compensating Research Participants?

  Should we be compensating research participants? And is that even a question worth asking? Lindsay McNair, MD, and Ken Getz say yes despite recent data that doesn't point to a clear ROI.

• Examining The Potential Of P-tau217 To Provide Earlier Diagnosis Of Alzheimer's

  P-tau217 blood tests could accelerate Alzheimer’s diagnosis. Lilly’s Nino Sireci, MD, MSc, explains the research, evidence thus far, potential clinical use, and next steps.

• The 50-Page Monitoring Report And The Illusion Of Control

  A massive decentralized trial showed why more monitoring doesn’t always mean more control — and how risk-based oversight can reveal what truly matters.

• Autoimmune Drugs For Women: What To Bring To The Clinic

  Autoimmune disease is one of the most sex-skewed categories in medicine. Sex, reproductive status, and hormonal state should not be treated as background noise. 

• The Real Cost Of Sites Working Without An Enforceable Agreement: Why Your Site's Quality Of Earnings Is Suspect

  Starting site work before an enforceable agreement may look like flexibility, but it can drain leverage, create unrecoverable costs, and raise financial reporting and GCP concerns.

• The U.S. Clinical Trial Recruiting Pipeline Report – August 2026

  This WhichTrial report breaks down which drug trials are growing the most and the least, drugs that are no longer being studied, and new drugs to the clinic from July and August.

• How VNS-REHAB Aims To Improve Stroke Recovery After Patients Have Plateaued

  Learn how a stroke trial standardized intensive therapy, sustained patient adherence, and exposed access barriers after FDA approval.

• Resensitizing Treatment-Resistant Cancer Holds Promise Over Replacing Once-Efficacious Therapies

  John Yu, MD, of Kairos Pharma, explains why reversing treatment resistance could extend the life of proven cancer therapies and improve patient outcomes.